According to a new report by Allied Market Research, titled, “World IV Ibuprofen Market - Opportunities and Forecasts, 2022 - 2030”, the global intravenous (IV) ibuprofen market is projected to reach $15.48 million by 2030. The pain indication segment accounted for over three-fourths share in 2015 and is expected to maintain its dominance throughout the forecast period.
Get Free Sample PDF Here>>> https://www.alliedmarketresearch.com/request-sample/1387
The major factors that boost the market growth include, increase in adoption of intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property. The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals. The IV Ibuprofen market is estimated to grow at a CAGR of 13.4% during 2021 and 2030.
Adults end user segment accounted for major share in 2020, and is projected to maintain this trend throughout the forecast period. Pediatrics is projected to be the fastest growing end user segment, owing to the growing need for rapid pain and fever management in children (to avoid damage caused by inflammation and high body temperature) and increasing awareness about the use of IV Ibuprofen in children.
Key Findings: Pain is projected to be the fastest growing indication segment. China IV Ibuprofen market is expected to grow at the fastest CAGR of 15.2% from 2021 to 2030. United States was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
The US is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.
Ask For More Details>>> https://www.alliedmarketresearch.com/purchase-enquiry/1387
The IV Ibuprofen market is dominated by Cumberland Pharmaceuticals and is actively engaged in research for the development of novel IV Ibuprofen products. The key ibuprofen companies profiled in this report are AFT Pharmaceuticals, Cumberland Pharmaceuticals Inc., Dano Health Group, Grifol, Harbin Gloria Pharmaceuticals Co., Ltd, Hyloris Pharmaceuticals SA, Pharma Bavaria International, Recordati, SG pharma, and XGEN.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
